Home LiteratureArticle Details
PMID: 8334995 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation.

The EMBO journal ·Vol. 12 ·No. 7 ·1993-07-00 ·Pages 2789-97

Shaulian E, Zauberman A, Milner J, Davies EA, Oren M

Abstract

The p53 tumor suppressor protein can bind tightly to specific sequence elements in the DNA and induce the transactivation of genes harboring such p53 binding sites. Various lines of evidence suggest that p53 binds to its target site as an oligomer. To test whether oligomerization is essential for the biological and biochemical activities of p53, we deleted a major part of the dimerization domain of mouse wild-type p53. The resultant protein, termed p53wt delta SS, was shown to be incapable of forming detectable homo-oligomers in vitro and is, therefore, likely to be predominantly if not exclusively monomeric. In agreement with the accepted model, p53wt delta SS indeed failed to exhibit measurable DNA binding in vitro. Surprisingly, though, it was still capable of suppressing oncogene-mediated transformation and of transactivating in vivo a target gene containing p53 binding sites. These findings indicate that dimerization-defective p53 is biologically active and may engage in productive sequence-specific DNA interactions in vivo. Furthermore, p53 dimerization probably leads to cooperative binding to specific DNA sequences.

MeSH Terms
Amino Acid Sequence Animals Biopolymers Cell Transformation, Neoplastic/genetics Cells, Cultured DNA/metabolism Humans Molecular Sequence Data Mutation Protein Binding Protein Conformation Transcriptional Activation Tumor Suppressor Protein p53/chemistry,genetics,metabolism
Chemicals
Biopolymers Tumor Suppressor Protein p53 DNA
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Shaulian E
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
Zauberman A
Milner J
Davies E A
Oren M
References (48)
48 references, click to expand
  1. The MCK enhancer contains a p53 responsive element.
    Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4570-1 PMID: 1647009
  2. Identification of p53 as a sequence-specific DNA-binding protein.
    Science. 1991 Jun 21;252(5013):1708-11 PMID: 2047879
  3. The role of p53 in the normal control of cell proliferation.
    Curr Opin Cell Biol. 1991 Apr;3(2):282-6 PMID: 1953903
  4. A DNA binding domain is contained in the C-terminus of wild type p53 protein.
    Nucleic Acids Res. 1991 Oct 11;19(19):5191-8 PMID: 1923804
  5. Wild-type p53 can down-modulate the activity of various promoters.
    Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):9979-83 PMID: 1946467
  6. Dimerization of a specific DNA-binding protein on the DNA.
    Science. 1992 Jan 10;255(5041):203-6 PMID: 1553548
  7. A transcriptionally active DNA-binding site for human p53 protein complexes.
    Mol Cell Biol. 1992 Jun;12(6):2866-71 PMID: 1588974
  8. Oncogenic forms of p53 inhibit p53-regulated gene expression.
    Science. 1992 May 8;256(5058):827-30 PMID: 1589764
  9. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest.
    EMBO J. 1992 Jun;11(6):2115-21 PMID: 1600943
  10. Cancer. p53, guardian of the genome.
    Nature. 1992 Jul 2;358(6381):15-6 PMID: 1614522
  11. Amplification of a gene encoding a p53-associated protein in human sarcomas.
    Nature. 1992 Jul 2;358(6381):80-3 PMID: 1614537
  12. Wild-type p53 activates transcription in vitro.
    Nature. 1992 Jul 2;358(6381):83-6 PMID: 1614538
  13. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.
    Cell. 1992 Jun 26;69(7):1237-45 PMID: 1535557
  14. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.
    Genes Dev. 1992 Jul;6(7):1143-52 PMID: 1628822
  15. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization.
    Oncogene. 1992 Aug;7(8):1513-23 PMID: 1321401
  16. Human wild-type p53 adopts a unique conformational and phosphorylation state in vivo during growth arrest of glioblastoma cells.
    Oncogene. 1992 Aug;7(8):1635-43 PMID: 1630823
  17. Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
    Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7491-5 PMID: 1323840
  18. p53 function and dysfunction.
    Cell. 1992 Aug 21;70(4):523-6 PMID: 1505019
  19. p53: the ultimate tumor suppressor gene?
    FASEB J. 1992 Oct;6(13):3169-76 PMID: 1397838
  20. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.
    Cell. 1992 Nov 13;71(4):587-97 PMID: 1423616
  21. Regulation of the specific DNA binding function of p53.
    Cell. 1992 Nov 27;71(5):875-86 PMID: 1423635
  22. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.
    Mol Cell Biol. 1992 Dec;12(12):5581-92 PMID: 1448088
  23. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
    Mol Cell Biol. 1993 Jan;13(1):301-6 PMID: 8417333
  24. mdm2 expression is induced by wild type p53 activity.
    EMBO J. 1993 Feb;12(2):461-8 PMID: 8440237
  25. Definition of a consensus binding site for p53.
    Nat Genet. 1992 Apr;1(1):45-9 PMID: 1301998
  26. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.
    EMBO J. 1993 Jul;12(7):2799-808 PMID: 8334996
  27. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene.
    Cell. 1984 Aug;38(1):119-26 PMID: 6088057
  28. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells.
    Nature. 1984 Dec 13-19;312(5995):646-9 PMID: 6095116
  29. Precise epitope mapping of the murine transformation-associated protein, p53.
    EMBO J. 1985 Mar;4(3):699-706 PMID: 2408882
  30. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.
    EMBO J. 1985 May;4(5):1251-5 PMID: 4006916
  31. Rearrangement of the p53 gene in human osteogenic sarcomas.
    Proc Natl Acad Sci U S A. 1987 Nov;84(21):7716-9 PMID: 2823272
  32. The p53 proto-oncogene can act as a suppressor of transformation.
    Cell. 1989 Jun 30;57(7):1083-93 PMID: 2525423
  33. Wild-type p53 can inhibit oncogene-mediated focus formation.
    Proc Natl Acad Sci U S A. 1989 Nov;86(22):8763-7 PMID: 2530586
  34. Transcriptional regulation by dimerization: two sides to an incestuous relationship.
    Cell. 1990 Apr 6;61(1):9-11 PMID: 2180585
  35. Protein-protein interactions facilitate DNA binding by the glucocorticoid receptor DNA-binding domain.
    J Biol Chem. 1990 Aug 15;265(23):14030-5 PMID: 1974254
  36. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.
    Cell. 1990 Aug 24;62(4):671-80 PMID: 2143698
  37. Presence of a potent transcription activating sequence in the p53 protein.
    Science. 1990 Aug 31;249(4972):1046-9 PMID: 2144363
  38. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Science. 1990 Aug 31;249(4972):1049-51 PMID: 2144364
  39. Different tumor-derived p53 mutants exhibit distinct biological activities.
    Science. 1990 Oct 5;250(4977):113-6 PMID: 2218501
  40. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135.
    J Mol Biol. 1990 Dec 5;216(3):481-4 PMID: 2258922
  41. Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
    Mol Cell Biol. 1991 Jan;11(1):12-9 PMID: 1986215
  42. Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein.
    Oncogene. 1990 Nov;5(11):1683-90 PMID: 2176282
  43. Genetic mechanisms of tumor suppression by the human p53 gene.
    Science. 1990 Dec 14;250(4987):1576-80 PMID: 2274789
  44. p53 mutations: gains or losses?
    J Cell Biochem. 1991 Jan;45(1):22-9 PMID: 2005181
  45. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.
    Cell. 1991 May 31;65(5):765-74 PMID: 2040013
  46. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication.
    Cell. 1991 Jun 14;65(6):1083-91 PMID: 1646078
  47. The p53 tumour suppressor gene.
    Nature. 1991 Jun 6;351(6326):453-6 PMID: 2046748
  48. p53 mutations in human cancers.
    Science. 1991 Jul 5;253(5015):49-53 PMID: 1905840
Article Info
Journal
The EMBO journal
Abbr.
EMBO J
ISSN
0261-4189
Published
1993-07-00
Pages
2789-97
Language
English
Region
England
NLM ID
8208664
PMCID
PMC413529
Subset
IM
Grants
NCI NIH HHS · R01 CA 40099 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]